01673nas a2200217   4500000000100000008004100001100001200042700001400054700001400068700001600082700001200098700001300110700001500123700001500138245010600153856005800259300001200317490000600329520110600335022001401441       2019                            d1 aWaman V1 aVedithi S1 aThomas SE1 aBannerman B1 aMunir A1 aSkwark M1 aMalhotra S1 aBlundell T00aMycobacterial genomics and structural bioinformatics: opportunities and challenges in drug discovery.  uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC6334779/  a109-1180 v83 a<p>Of the more than 190 distinct species of Mycobacterium genus, many are economically and clinically important pathogens of humans or animals. Among those mycobacteria that infect humans, three species namely Mycobacterium tuberculosis (causative agent of tuberculosis), Mycobacterium leprae (causative agent of leprosy) and Mycobacterium abscessus (causative agent of chronic pulmonary infections) pose concern to global public health. Although antibiotics have been successfully developed to combat each of these, the emergence of drug-resistant strains is an increasing challenge for treatment and drug discovery. Here we describe the impact of the rapid expansion of genome sequencing and genome/pathway annotations that have greatly improved the progress of structure-guided drug discovery. We focus on the applications of comparative genomics, metabolomics, evolutionary bioinformatics and structural proteomics to identify potential drug targets. The opportunities and challenges for the design of drugs for M. tuberculosis, M. leprae and M. abscessus to combat resistance are discussed.</p>
  a2222-1751